MedTrace Logo

Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

NCT02303041 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-01-29

Study results available
· View outcomes & findings →

Summary

This pilot trial studies how well sonidegib and buparlisib work in treating patients with basal cell carcinoma that has spread to other places in the body. Sonidegib and buparlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Carcinoma, Basal Cell
  • Recurrent Skin Cancer
  • Skin Neoplasms
  • Basal Cell Nevus Syndrome

Interventions

DRUG

Buparlisib

Administered orally at starting dose of 80 mg/day

DRUG

Sonidegib

Administered orally at starting dose of 200 mg/day

Sponsors & Collaborators

Principal Investigators

  • Anne Lynn Chang, MD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2017-04-30
Completion
2017-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02303041 on ClinicalTrials.gov